Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are considered mutually exclusive in non-small cell lung cancer (NSCLC), especially in lung adenocarcinoma (LUAC). However, sporadic cases harboring concomitant EGFR and ALK alterations have been increasingly reported. There is no consensus opinion regarding the treatment of patients positive for both molecular alterations. NSCLC with EGFR/ALK coalterations should be separated into two subtypes: unifocal and multifocal LUAC. Here, we present an overview of the available literature regarding this rare group of patients to provide useful suggestions for therapeutic strategies.
JemalABrayFCenterMM, et al. Global cancer statistics. CA Cancer J Clin2011; 61: 69–90.
2.
KrisMGJohnsonBEBerryLD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA2014; 311: 1998–2006.
3.
RotowJBivonaTG.Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer2017; 17: 637–658.
4.
DeardenSStevensJWuYL, et al. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol2013; 24: 2371–2376.
5.
LeeCKBrownCGrallaRJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst2013; 105: 595–605.
6.
HeonSYeapBYLindemanNI, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res2012; 18: 4406–4414.
7.
ZhaoFXuMLeiH, et al. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis. PloS One2015; 10: e0117333.
8.
ShawATYeapBYMino-KenudsonM, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol2009; 27: 4247–4253.
9.
SodaMChoiYLEnomotoM, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature2007; 448: 561–266.
10.
LinJJRielyGJShawAT.Targeting ALK: precision medicine takes on drug resistance. Cancer Discov2017; 7: 137–155.
11.
LinYTWangYFYangJC, et al. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol2014; 9: 1720–1725.
12.
DjalalovSBecaJHochJS, et al. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol2014; 32: 1012–1019.
13.
GainorJFVargheseAMOuSH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res2013; 19: 4273–4281.
14.
SasakiTKoivunenJOginoA, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res2011; 71: 6051–6060.
15.
LeeJKKimTMKohY, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer2012; 77: 460–463.
16.
KuoYWWuSGHoCC, et al. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol2010; 5: 2039–2040.
17.
TiseoMGelsominoFBoggianiD, et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer2011; 71: 241–243.
18.
PopatSVieiradeAraujoAMinT, et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol2011; 6: 1962–1963.
19.
ChenXZhangJHuQ, et al. A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene. Lung Cancer2013; 81: 308–310.
20.
PaezJGJannePALeeJC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science2004; 304: 1497–1500.
21.
SekineIYamamotoNNishioK, et al. Emerging ethnic differences in lung cancer therapy. Br J Cancer2008; 99: 1757–1762.
22.
WangXWangMMacLennanGT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst2009; 101: 560–570.
23.
FanJDaiXWangZ, et al. Concomitant EGFR mutation and EML4-ALK rearrangement in lung adenocarcinoma is more frequent in multifocal lesions. Clin Lung Cancer2019; 20: e517–e530.
24.
SantelmoCRavaioliABarzottiE, et al. Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib. Lung Cancer2013; 81: 294–296.
25.
BaldiLMengoliMCBisagniA, et al. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. Lung Cancer2014; 86: 291–295.
26.
CaliezJMonnetIPujalsA, et al. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement.] Rev Mal Respir2017; 34: 576–580.
27.
LiYSuSCaiG, et al. Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: a case report and review of the literature. Molec Clin Oncol2017; 7: 173–182.
28.
YangJJZhangXCSuJ, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res2014; 20: 1383–1392.
29.
CaiWLinDWuC, et al. Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinoma. J Clin Oncol2015; 33: 3701–3709.
30.
WonJKKeamBKohJ, et al. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol2015; 26: 348–354.
31.
Lo RussoGImbimboMCorraoG, et al. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget2017; 8: 59889–59900.
32.
SchneiderFDerrickVDavisonJM, et al. Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. Mod Pathol2016; 29: 735–742.
33.
WuCZhaoCYangY, et al. High discrepancy of driver mutations in patients with NSCLC and synchronous multiple lung ground-glass nodules. J Thorac Oncol2015; 10: 778–783.
34.
ChenKChenWCaiJ, et al. Favorable prognosis and high discrepancy of genetic features in surgical patients with multiple primary lung cancers. J Thorac Cardiovasc Surg2018; 155: 371–379.e1.
35.
LiuYZhangJLiL, et al. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun2016; 7: 13200.
36.
LiuMHeWXSongN, et al. Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities. Eur J Cardiothorac Surg2016; 50: 909–913.
37.
TravisWDBrambillaENoguchiM, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc2011; 8: 381–385.
38.
TravisWDBrambillaENicholsonAG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol2015; 10: 1243–1260.
39.
SunWFengLYangX, et al. Clonality assessment of multifocal lung adenocarcinoma by pathology evaluation and molecular analysis. Hum Pathol2018; 81: 261–271.
40.
ThunnissenEBeasleyMBBorczukAC, et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma: an international interobserver study. Mod Pathol2012; 25: 1574–1583.
41.
GirardNOstrovnayaILauC, et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res2009; 15: 5184–5190.
42.
DacicSIonescuDNFinkelsteinS, et al. Patterns of allelic loss of synchronous adenocarcinomas of the lung. Am J Surg Pathol2005; 29: 897–902.
43.
Rami-PortaRAsamuraHTravisWD, et al. Lung cancer: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin2017; 67: 138–155.
44.
WarthAMacher-GoeppingerSMuleyT, et al. Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. Eur Respir J2012; 39: 1437–1442.
45.
GazdarARobinsonLOliverD, et al. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol2014; 9: 456–463.
46.
FanJWuJHuangB, et al. Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report. Diagn Pathol2020; 15: 42.
